Related by context. All words. (Click for frequent words.) 79 Anti Tumor 79 Prolongs Survival 77 Anti Tumor Activity 77 Preclinical Study 77 Phase 2b Clinical Trial 77 Kinase Inhibitor 76 Adjuvant Treatment 76 Drug Candidate 76 Clinical Outcome 76 Phase 2b Trial 76 Preclinical Data 76 Improves Survival 76 Polymerase Inhibitor 75 Tyrosine Kinase Inhibitor 75 Clinical Trial Results 75 Presents Preclinical Data 75 Meets Primary Endpoint 75 Adjuvant Chemotherapy 75 Novel Oral 75 Patients Treated With 75 Hsp# Inhibitor 74 See CLINICAL PHARMACOLOGY 74 Smooth Muscle 74 Phase 2a Clinical Trial 74 Orally Active 74 Oral Fingolimod 74 Anticancer Drug 74 Pharmacokinetic Study 74 Antitumor 74 IND Application 74 JAK2 Inhibitor 74 Demonstrates Efficacy 74 Aurora Kinase 74 Inhibits 74 Inhaled Corticosteroids 74 Investigational Agent 74 Small Molecule 74 Phase IIb Clinical Trial 74 Protease Inhibitor 74 Phase Ib Clinical Trial 74 FDA Okays 74 Antitumor Activity 74 Mouse Model 74 Novel Compound 73 Pooled Analysis 73 Receives Orphan Drug Designation 73 Demonstrates Positive 73 Improves Outcomes 73 Confirmatory Phase 73 Novel Therapeutic 73 Files IND 73 Lung Cancer Trial 73 Shows Promise Against 73 Demonstrates Significant 73 RNAi Therapeutic 73 Phase 1b Clinical Trial 73 Study Evaluating 73 Lung Cancer Drug 73 Novel Antibiotic 73 Phase 2b Study 73 Attenuates 73 Immunomodulatory 73 Immune Responses 73 Present Preclinical Data 73 Lupus Drug 73 Investigational Drug 73 Epithelial Cell 73 FDA Approvals 73 Phase III Clinical Trial 73 Gene Variants 73 Dose Escalation 73 Anticancer Activity 73 Low Dose 73 Patients Receiving 73 Patient Enrollment 73 Infected Patients 73 Single Dose 73 First Patient Dosed 73 Appears Safe 73 Completes Patient Enrollment 73 Mimetics 72 Nicotine Vaccine 72 Allogeneic 72 Preclinical Models 72 J Clin 72 Skeletal Muscle 72 Cell Adhesion 72 Phase 2a Trial 72 AnaSpec Introduces 72 Systemic Delivery 72 Antigen Specific 72 Metastatic Renal Cell Carcinoma 72 Shows Promising 72 Relapsed Refractory 72 Phase IIb Trial 72 Peginterferon Alfa 2a 72 Kidney Function 72 Pharmacokinetics PK 72 Severe Sepsis 72 HDAC Inhibitor 72 Initiates Clinical Trial 72 Modulates 72 Granted Orphan Drug 72 Antiangiogenic 72 Initiates Clinical 72 Rheumatoid Arthritis Patients 72 Trial Evaluating 72 Potent Inhibitor 72 Mouse Models 72 Schizophrenia Treatment 72 Clinical Trial Evaluating 72 Dendritic Cells 72 Progenitor Cells 72 II Clinical Trial 72 Cardiotoxicity 72 Dose Ranging Study 72 Novel Mechanism 71 Pivotal Phase III 71 Statistically Significant 71 Treating Chronic 71 Renal Cell Carcinoma 71 Breast Cancer Cells 71 HCV Protease Inhibitor 71 Demonstrates Potent 71 Neurol 71 Treated Patients 71 Initiate Phase 71 Antiviral Activity 71 Pegylated 71 Solid Tumor 71 Disease Progression 71 Drug Shows Promise 71 Successfully Completes Phase 71 Hormone Refractory Prostate Cancer 71 Showed Significant 71 Demonstrates Potential 71 Prostate Cancer Vaccine 71 Bone Metastases 71 Osteoporosis Treatment 71 Gastric Cancer 71 Androgen Receptor 71 Proteasome 71 Brain Metastases 71 Oral Formulation 71 Survival Benefit 71 Recombinant Human 71 Parathyroid Hormone 71 Randomized Clinical Trial 71 Inflammatory Arthritis 71 Investigational Compound 71 Pharmacodynamics 71 Relapsing Multiple Sclerosis 71 Completes Enrollment 71 NDA Submission 71 Improved Survival 71 Metastatic Melanoma 71 Anti Inflammatory Drug 71 Fungal Infections 71 Advanced Melanoma 71 FDA Accepts 71 Signaling Pathway 71 Tumor Suppressor Gene 71 Submits NDA 71 Initiate Phase III 71 Phase III Trial 71 Demonstrates Sustained 71 Previously Treated 71 Shows Efficacy 71 Liposomal 71 Fast Skeletal Troponin 71 Study Demonstrates 71 Protein Synthesis 71 Treatment Naïve 71 Crit Rev 71 Prostate Cancer Patients 71 Aptamer 71 Prognostic Factors 71 Phase IIa Clinical Trial 71 Polymorphisms 71 Demonstrated Significant 71 Therapeutic Antibody 71 IND Filing 71 Adjuvant Therapy 71 Dose Response 71 Interferon Gamma 70 Histone Deacetylase 70 Chronic Hepatitis C 70 Pivotal Study 70 Bosutinib 70 Controlled Study 70 Plus Ribavirin 70 Controlled Trial 70 Phosphorylation 70 Critically Ill Patients 70 Combo Therapy 70 Initiates Phase III 70 FDA Clears 70 Investigational Treatment 70 Osteoporosis Drug 70 Vaccine Adjuvant 70 CYP#A# CYP#D# 70 Conjugate 70 Slow Progression 70 Protein Involved 70 Clinical Evaluation 70 Pivotal Phase II 70 Estrogen Receptor 70 Myeloid 70 Anticancer Agent 70 Angiogenic 70 Prospective Randomized 70 Complicated Skin 70 Receptor Agonist 70 Therapy Reduces 70 Antiviral Therapy 70 Soft Tissue Sarcoma 70 Hypertensive Patients 70 Cyclophosphamide 70 Genes Predict 70 Dose Ranging 70 Topical Treatment 70 Transdermal Patch 70 Shows Statistically Significant 70 Endothelial Cells 70 Nucleoside 70 Heart Failure Patients 70 Effectively Treats 70 Subgroup Analysis 70 Cholesterol Lowering Drug 70 Prognostic Significance 70 Autologous Stem Cell Transplantation 70 Transcription Factor 70 Double Blind Randomized 70 Receptor Antagonist 70 Cyclooxygenase 2 70 Multiple Ascending Dose 70 Sex Hormones 70 Achieves Primary Endpoint 70 Randomized Double Blind 70 Kidney Transplant Patients 70 Rotavirus Vaccine 70 Kinase Inhibitors 70 Plaque Psoriasis 70 Drug Combo 70 Diabetic Foot Ulcer 70 Dose Escalation Study 70 Protease 70 Beta Amyloid 70 Patients Suffering 70 Hepatic Encephalopathy 70 Demonstrate Significant 70 Mutational 70 Prognostic Value 70 Node Positive 70 Pivotal Phase 70 fosbretabulin 70 Rheumatoid Arthritis Drug 70 Proc Am Soc 70 Respiratory Virus 70 Neurosurg 70 Protein Kinase 70 JAK Inhibitor 70 Percutaneous Tibial Nerve Stimulation 70 Drug Fails 70 Therapy Improves 70 Induces 70 Significantly Improves 70 Tumor Angiogenesis 70 Clinical Efficacy 70 Antifungal 70 Vitro Activity 70 Disease Modifying 70 Unfractionated Heparin 70 Interferon Alfa 70 Hepatocellular Carcinoma 70 Oncol 70 Male Contraceptive 70 Significantly Improved 70 Elderly Patients 70 Phospholipase A2 70 Immunotherapeutic 70 Fewer Side Effects 70 Patients Treated 69 Protein Linked 69 Inflammatory Disease 69 Quantitation 69 Oncolytic Reovirus 69 Left Ventricular 69 Patients Undergoing 69 Treatment Naïve Patients 69 Teva Provides Update 69 Tumor Response 69 Renal Cell Cancer 69 Lowers Risk 69 Laryngeal Cancer 69 HER2 Positive 69 Neuroendocrine Tumors 69 Recurrent Breast Cancer 69 Drug Prevents 69 Clin Oncol 69 Oral Mucositis 69 Test Detects 69 Double Blind Placebo 69 Radiation Induced 69 Breast Cancer Recurrence 69 Is Well Tolerated 69 Genes Linked 69 Eluting Stent 69 Gene Silencing 69 Prostate Cancer Progression 69 Curr Opin 69 Randomized Phase II 69 Newly Diagnosed Multiple Myeloma 69 Protease Inhibitors 69 Adenoviral 69 metastatic malignant 69 Collaborators Present 69 Adenoma 69 Combination REOLYSIN R 69 Combination Treatment 69 Gene Variant 69 J Am Coll 69 Develop Novel 69 Testis 69 Blood Pressure Drug 69 Hepatocellular 69 Induction Therapy 69 Prophylactic Treatment 69 Cell Transplants 69 Benign Prostatic Hyperplasia 69 Secondary Hyperparathyroidism 69 Vascular Disrupting Agent 69 Advanced Renal Cell 69 Synthetic Peptide 69 Peripheral Arterial 69 Hepatitis C Treatment 69 Safety Tolerability 69 Non Invasive Treatment 69 Am J Clin 69 Well Tolerated 69 Autoimmune Disease 69 Therapeutic Efficacy 69 Unresectable 69 Orthostatic Hypotension 69 Gene Linked 69 Pivotal Trial 69 Monotherapy 69 Clinical Trial Data 69 Recurrent Glioblastoma 69 First Patient Enrolled 69 Transdermal Delivery 69 Combination Clinical Trial 69 Investigational Oral 69 Diabetic Nephropathy 69 Levels Linked 69 Nilotinib 69 Arterial Disease 69 Myelodysplastic Syndromes 69 Randomized Study 69 Neoadjuvant Chemotherapy 69 Tumor Necrosis Factor 69 Leukemia Cells 69 Circulating Tumor Cells 69 Anticancer Compound 69 Beneficial Effects 69 Histone 69 Predict Prostate Cancer 69 Minimally Invasive Treatment 69 Initiates Clinical Trials 69 Ovarian Cancer Patients 69 Small Molecule Inhibitors 69 Cutaneous T 69 T Lymphocyte 69 Abstract Number 69 Regenerative Cells 69 Immunostimulatory 69 Placebo Controlled Study 69 Breast Tissue 69 Lung Cancer Patients 69 Nephrol 69 Prodrug 69 Potent Anti 69 Randomized Phase 69 Arch Facial Plast 69 Anticancer Drugs 69 Artery Disease 69 Efficacious 69 Posaconazole 69 Epidermal Growth Factor Receptor 69 Liver Failure 69 Kidney Transplant Recipients 69 Dehydrogenase 69 Chemotherapy Induced 69 Interferon Beta 69 Humanized Anti 69 Cancer Biomarkers 69 Initiates Dosing 69 Breast Tumors 69 Cytochrome P# 69 Refractory Hodgkin Lymphoma 69 Liver Tumors 69 Lymphoid 69 Ophthalmol 69 Myeloma Patients 69 Placebo Controlled Trial 69 Pegylated Liposomal Doxorubicin 69 Glufosfamide 69 Erectile Dysfunction Drug 69 Molecular Mechanism 69 Gastrointestinal Stromal Tumors 69 Transplant Patients 69 Initiate Clinical Trial 69 BiTE Antibody 68 Predict Response 68 Lung Tumors 68 Refractory Angina 68 Reduces Pain 68 Cannabinoid 68 Intravenous Formulation 68 Hematological Malignancies 68 Rheumatol 68 Announces FDA Clearance 68 Files Investigational 68 Respiratory Distress 68 Cancer Vaccines 68 Sirolimus Eluting Stent 68 Chronic Renal Failure 68 Prolongs Life 68 Risk Stratification 68 Cell Transplant 68 Ischemic 68 Receives Orphan Drug 68 Suppresses 68 Genetic Mutation 68 Initiates Phase II 68 platform HDL Mimetic 68 Lowers Blood Pressure 68 Hypercholesterolemia 68 Imaging Techniques 68 Ecallantide 68 Synthase 68 Late Breaker 68 Epithelial 68 Nat Clin Pract 68 Hematological Cancers 68 Fondaparinux 68 Chemokine Receptor 68 Slows Progression 68 Chronic Lymphocytic Leukemia 68 Novel Treatments 68 Smallpox Vaccine 68 Treatment Reduces 68 Anti Angiogenic 68 Bucindolol 68 Highly Accurate 68 Randomized Clinical Trials 68 Gene Mutation 68 Tumor Suppressor 68 Localized Prostate Cancer 68 Pulmonary Arterial Hypertension 68 Lung Cancer Survival 68 Peripheral Blood 68 Cardiac Function 68 Signaling Pathways 68 Knee Osteoarthritis 68 Patient Enrolment 68 Preclinical Evaluation 68 Oral Calcitonin 68 Inflammatory Markers 68 Platelet Function 68 Presents Positive 68 Molecular Basis 68 Inflammatory Pain 68 AVI BioPharma Announces 68 Long Term Efficacy 68 Therapeutic Vaccine 68 Study Showed 68 Immunomedics Announces 68 Beta Blocker 68 Ridaforolimus 68 Data Suggest 68 Relapsing Remitting Multiple Sclerosis 68 Diabetic Neuropathy 68 Factor Receptor 68 Genetic Variation 68 Treatment Experienced 68 Anesth 68 Advanced Colorectal Cancer 68 Efficacy Trial 68 J Child Adolesc 68 Oral Insulin 68 Myocardial Ischemia 68 Improve Survival 68 IN PATIENTS WITH 68 Mylan Receives Approval 68 Postmenopausal Osteoporosis 68 Combination Therapy 68 Significantly Reduces 68 Drug Resistant 68 Less Invasive 68 First Patient Treated 68 Diffuse Large B 68 Initiates Enrollment 68 Coronary Arteries 68 Pediatric Patients 68 TO AVOID PREGNANCY WHILE 68 Epilepsy Drug 68 Contrast Agent 68 Gout Drug 68 Pre Cancerous 68 Could Predict 68 Oral Presentations 68 Pediatr 68 Polymorphism 68 Adult Stem Cell Therapy 68 Demonstrates Statistically Significant 68 Meta Analysis 68 Targeted Therapy 68 Diagn 68 Melphalan 68 Enlarged Prostate 68 orally administered inhibitor 68 Previously Untreated 68 J Pediatr 68 Chronic Hepatitis B 68 Binding Protein 68 Renal Function 68 Acute Heart Failure 68 J Shoulder Elbow 68 Glucocorticoid 68 Intracranial Aneurysms 68 Sipuleucel T 68 Somatostatin 68 Carotid Stenting 68 Ovarian Cancers 68 Fibrinogen 68 Bortezomib 68 Peginterferon 68 Induces Apoptosis 68 Monoclonal Antibody 68 Immunosuppression 68 Adjunctive Therapy 68 Advanced Prostate Cancer 68 Randomized Trials 68 Increased Mortality 68 Autoimmune Diseases 68 Vaccine Adjuvants 68 Vicriviroc 68 Metastatic Prostate Cancer 68 sunitinib Sutent ® 68 Antitumor activity 68 Cancer Stem Cells 68 Genes Involved 68 Resubmission 68 Diagnostic Tests 68 Statin Therapy 68 Fulvestrant 68 Cognitive Deficits 68 Thromboembolic 68 Protein Expression 67 Follicular Lymphoma 67 Disord 67 Biologic Therapy 67 Treatment Regimen 67 Lentiviral 67 Left Ventricular Dysfunction 67 Decitabine 67 Phase III Trials 67 Versus Placebo 67 Predict Breast Cancer 67 Resistant Hypertension 67 Isavuconazole 67 Tocopherol 67 Sustained Release 67 Assay Kits 67 Thrombotic 67 Lenalidomide 67 Liver Metastases 67 Eur J 67 Viral Load 67 Proves Effective 67 Treatment Naive HIV 67 Hemodialysis Patients 67 familial amyloidotic polyneuropathy FAP 67 PEG IFN 67 PRN FDA Approves 67 IIa Clinical Trial 67 Receives Milestone Payment 67 Protein Biomarker 67 Immune Cell 67 Hormone Receptor Positive 67 Tezampanel 67 HER2 Positive Breast Cancer 67 Capsules CII 67 Pathol 67 Newly Diagnosed 67 Mycophenolate Mofetil 67 Endocrinol Metab 67 Synta Announces 67 Tumor Growth 67 Sapacitabine 67 Invasive Fungal Infections 67 Pharmacodynamic 67 Therapeutic Potential 67 Placebo Controlled 67 Stent Coating 67 Endocrinol 67 Antiplatelet 67 Extracellular Matrix 67 FDA Approves Drug 67 Tyrosine Kinase 67 Topline Results 67 Endothelial 67 Inactivation 67 Therapeutic Vaccines 67 Glatiramer Acetate 67 Abstract Accepted 67 Ebola Vaccine 67 Mol Cell 67 Lupus Nephritis 67 Contrast Agents 67 Carcinomas 67 ara C 67 Postmenopausal Women 67 Stem Cell Treatment 67 Cancer Res 67 Multiple Myeloma Patients 67 Electrical Stimulation 67 Cardiovascular Disease Risk 67 beta 1a 67 Epratuzumab 67 Suppl. 67 #-# Full Text 67 Cardiovasc 67 Randomized Double blind 67 Newly Identified 67 DNA Methylation 67 Secretase 67 Myoblast 67 Vaginal Gel 67 Angiotensin Converting Enzyme 67 Neovascularization 67 Study Casts Doubt 67 Tyrosine Kinase Inhibitors 67 Hematopoietic 67 Cardiol 67 Breast Ultrasound 67 Oncolytic 67 Migraine Drug 67 Fast Track Status 67 Metabolic Disease 67 Aggressive Prostate Cancer 67 Prostatic 67 Castration Resistant Prostate Cancer 67 #:#-# [031] 67 Malignant Melanoma 67 Peroxisome Proliferator Activated Receptor 67 Advanced Ovarian Cancer 67 PEGylated Fab fragment 67 FASEB J. 67 J Appl 67 Biomarker Study 67 Patent Covering 67 Invasive Breast Cancer 67 mediated inhibition 67 Hematopoietic Stem Cells 67 pralatrexate injection folate analogue 67 Testosterone Patch 67 Psoriasis Drug 67 Insulin Resistance 67 Treatment Naive 67 Breast Cancer Metastasis 67 Often Misdiagnosed 67 Testosterone Gel 67 Paclitaxel Carboplatin 67 Pharmacother 67 Hepatitis C Genotype 67 Oligonucleotides 67 Nucleic Acids Res 67 Antisense Drug 67 Uric Acid 67 Expanded Indication 67 Cardiac Troponin 67 Subtypes 67 Autoimmune Disorders 67 Epoetin Alfa 67 Artificial Pancreas 67 Commences Phase 67 Mg Usa 67 Arch Neurol 67 Antiplatelet Therapy 67 Sirolimus Eluting 67 Treating Heart Failure 67 Non Inferiority 67 Generic Version 67 Lymphocytic 67 Shown Effective 67 Selective Inhibitor 67 urate oxidase 67 HCV Genotype 67 J Am Acad 67 Amniotic Fluid 67 CYT# potent vascular disrupting 67 Oligonucleotide 67 Reductase 67 Initiated Phase 67 Chronic Heart Failure 67 Virus Infection 67 Muscle Wasting 67 Selective Cardiac Myosin 67 Susceptibility Testing 67 Phase IIa Trial 67 Breast Cancer Stem Cells 67 Lung Cancer Treatment 67 Telaprevir VX 67 Chronic Sinusitis 67 Valve Replacement 67 Mg Uk 67 ACE Inhibitors 67 Migraine Treatment 67 Tumor Cells 67 Pivotal Trials 67 Fracture Risk 67 Contrast Enhanced 67 #:#-# [020] 67 Helps Predict 67 Cervical Dysplasia 67 Pneumococcal Vaccine 67 Soluble CD# 67 Sangamo BioSciences Announces 67 Neural Stem Cell 67 Leukemias 67 Randomised 67 Lipid Lowering 67 Significantly Reduced 67 Antisense Oligonucleotides 67 Predict Risk 67 Shows Promise 67 Neural Stem Cells 67 Prostate Tumors 67 Muscle Cells 67 Reduces Risk 67 Highly Selective 67 Novel Method 67 Systemic Sclerosis 67 Immunogenicity 67 Hematologic Malignancies 67 Lubiprostone 67 Proven Effective 67 Left Atrial 67 Drug Eluting 67 Colorectal Cancer Patients 67 Safinamide 67 Immunol 67 protein tyrosine phosphatase 1B 67 Ovarian Cancer Treatment 66 Targeted Therapies 66 Int J 66 Therapy Shows Promise 66 Clinical Validation 66 Aeolus Pharmaceuticals Announces 66 Dasatinib 66 Novel Protein 66 FDA APPROVES 66 R lenalidomide 66 Cytotoxicity 66 Patients Enrolled 66 Blinatumomab 66 pan HDAC inhibitor 66 Immune Cells 66 Epitopes 66 Left Ventricular Hypertrophy 66 Non Alcoholic Steatohepatitis 66 Cell Lymphoma 66 Hypertrophy 66 Chronic Myeloid Leukemia 66 Significant Improvements 66 Receives Fast Track 66 Conjugated 66 Thiazolidinediones 66 Treatment Regimens 66 Immune Therapy 66 Analytical Tool 66 Systolic Blood Pressure 66 Renal Cancer 66 Stent Restenosis 66 5 Fluorouracil 66 Myocardial Perfusion Imaging 66 Non Responders 66 poly ADP ribose polymerase 66 Phase III Pivotal Trial 66 Mesenchymal Stem Cells 66 ALN HPN 66 Incretin 66 Cell Proliferation 66 Psychol 66 Septic Shock 66 Treat Anemia 66 Watchful Waiting 66 Prevent Stroke 66 Begin Clinical Trials 66 Malaria Vaccine 66 Randomized Double Blind Placebo 66 Abnormality 66 Subtype 66 Skin Lesions 66 Mucosal 66 Inhalation Solution 66 Medoxomil 66 arginine vasopressin AVP 66 TB Vaccine 66 Dry Powder Inhalers 66 Long Term Survival 66 Study Evaluates 66 Mutagenesis 66 Protein Structures 66 Prove Effective 66 Human Monoclonal Antibodies 66 Avian Flu Vaccine 66 Oxidase 66 Diagnostic Criteria 66 Hernia Repair 66 Reduced Risk 66 Differential Diagnosis 66 Tumor Targeting 66 Microtubule 66 Solid Tumors 66 von Willebrand Factor 66 Bone Marrow Cells 66 Preclinical Efficacy 66 Gene Variation 66 Metabolic Disorder 66 Innate Immune 66 Infect Dis 66 Prostate Cancer Survival 66 Chemotherapy Improves 66 Peginterferon Alfa 2b 66 Taro Receives 66 Personalized Immunotherapy 66 Non Alcoholic Fatty 66 Î ² 66 TNF Alpha 66 Antidepressants Linked 66 Chronic Myelogenous Leukemia 66 Atopic Dermatitis 66 Cholesterol Drug 66 Soy Isoflavones 66 Pharmacologic 66 Potentially Fatal 66 Tablet Formulation 66 GW# [003] 66 Germline 66 ORLive Presents 66 Neoadjuvant 66 Researchers Identify 66 Hepatitis B Virus 66 Molecular Diagnostic Test 66 Best Pract Res 66 Treating Depression 66 RNAi Therapeutics 66 Device Helps 66 Licenses Novel 66 Monoclonal 66 Apoptotic 66 Romidepsin 66 Novel Small Molecule 66 Myocardial Perfusion 66 Malignant Glioma 66 Autoantibodies 66 hematological parameters 66 Infarct 66 Neuroprotection 66 Successfully Treated 66 Treatment Naive Patients 66 Metabolic Efficiency 66 Forodesine 66 Hematological 66 Sleep Disturbances 66 Inhibits Growth 66 Oral Spray 66 Randomized Controlled Trials 66 Dose Finding 66 Gets FDA Clearance 66 Recombinant Protein 66 Receptor Antagonists 66 Granulocyte Colony Stimulating Factor 66 Arrhythmogenic 66 Cell Differentiation 66 Breast Carcinoma 66 Aflibercept 66 Intravitreal 66 Retinoic Acid 66 Endothelial Function 66 Receives Approvable Letter 66 Companion Diagnostic 66 Free Full Text 66 Polymerase 66 Anti Inflammatory Drugs 66 Atypical Hemolytic Uremic Syndrome 66 Dose Reduction 66 P#Y# [001] 66 abstr 66 Insulin Sensitivity 66 Tumor Progression 66 Remission Maintenance 66 Imaging Technique 66 Initiates Phase 66 dasatinib Sprycel ® 66 Fecal Incontinence 66 Deforolimus 66 Bronchodilator 66 Human Monoclonal Antibody 66 ARRY # 66 Hematol 66 Physiol 66 Genetic Variant 66 Suppl 66 PEGylated anti 66 Squamous Cell Carcinoma 66 Lung Cancers 66 Neuroprotective Effects 66 Bevacizumab 66 Orally administered 66 Activator CK # 66 Replacement Therapy 66 Pharmacyclics Announces 66 Metastatic Colorectal Cancer 66 Anti Nausea 66 Cellular Immunotherapy 66 Chemoradiation 66 Reduces Mortality 66 TNF Tumor Necrosis Factor 66 Tanespimycin 66 Epoetin 66 Virus Linked 66 Aerosolized 66 Antibody Drug Conjugate 66 Survival Rate 66 Fludarabine 66 Int J Obes Relat 66 ISTODAX ® 66 CLINICAL PHARMACOLOGY 66 Cancer Cells 66 Interferon Alpha 66 Janus kinase 66 Cancer Treatments 66 Total Knee Arthroplasty 66 Treatment Shows Promise 66 Telik Announces 66 Hormone Replacement 66 imatinib Gleevec ® 66 Anticoagulant 66 Transplant Rejection 66 Bazedoxifene 66 Fibroblast 66 By JENNIFER LEARN 66 2 methoxyestradiol 66 Poster Discussion 66 Radiol 66 Multicenter Trial 66 ST Segment Elevation 66 Mutation Detection 66 EntreMed Presents 66 Chemotherapeutic Agents 66 Initiates Phase 2b 66 Helps Identify 66 Recurrent Ovarian Cancer 66 Cytotoxic 66 Clostridium difficile Infection 66 Vildagliptin 66 oral prodrug 66 Novel Vaccine 66 #:#-# [023] 66 myelodysplastic myeloproliferative diseases 66 Br J 66 Disease Modification 66 Blood Pressure Lowering 66 J Am Soc 65 Stakeholder Opinions 65 Schizophrenia Drug 65 Reports Preclinical Data 65 Denufosol 65 Ann Rheum Dis 65 Vaccine Shows Promise 65 Toxicol 65 Bioresorbable 65 Myelofibrosis 65 Muscarinic 65 Biocompatibility 65 Reperfusion Injury 65 Genetic Marker 65 Poster Presentations 65 Naive Patients 65 Phase 2a Study 65 Inhibitory 65 Emerging Therapies 65 PDUFA Date 65 Preclinical Studies 65 TNF Blockers